Sign In
Buy ARVN
$8.03
-0.270 (-3.25%)
At Close: Jul 31, 2026
Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study
06:58am, Tuesday, 11'th Mar 2025
Pfizer and Arvinas' experimental drug to treat a type of breast cancer met the main goal in a late-stage study, the companies said on Tuesday.
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
06:45am, Tuesday, 11'th Mar 2025
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –
Arvinas to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 04'th Mar 2025
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
11:00am, Monday, 03'rd Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 228.9% in Arvinas (ARVN). While the effectiveness of this highly sought-after metric is questionable, the posit
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
01:06pm, Friday, 14'th Feb 2025
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
10:56am, Friday, 14'th Feb 2025
The mean of analysts' price targets for Arvinas (ARVN) points to a 235.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
These Analysts Revise Their Forecasts On Arvinas After Q4 Results
12:04pm, Wednesday, 12'th Feb 2025
Arvinas, Inc. ARVN reported worse-than-expected fourth-quarter sales results on Tuesday.
Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript
03:22pm, Tuesday, 11'th Feb 2025
Arvinas, Inc. (NASDAQ:ARVN ) Q4 2024 Earnings Conference Call February 11, 2025 8:00 AM ET Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - President and Chief Exe
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
09:15am, Tuesday, 11'th Feb 2025
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $2.53 per share a year ago.
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
07:00am, Tuesday, 11'th Feb 2025
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with ab
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
07:00am, Monday, 03'rd Feb 2025
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
10:00am, Saturday, 01'st Feb 2025
Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised to contact Danielle Peyton at [email protected]
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
12:00pm, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
12:05pm, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to con
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
12:00pm, Sunday, 26'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). Such investors are advised
